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ABSTRACT Markers of identified neuronal populations have previously suggested se-
lective degeneration of projection neurons in Huntington’s disease (HD) striatum. Interpre-
tations are, however, limited by effects of compensatory regulation and atrophy. Studies of
the vesicular monoamine transporter type-2 (VMAT2) and of the vesicular acetylcholine
transporter (VAChT) in experimental animals indicate that they are robust markers of
presynaptic integrity and are not subject to regulation. We measured dopamine and acetyl-
choline vesicular transporters to characterize the selectivity of degeneration in HD stria-
tum. Brains were obtained at autopsy from four HD patients and five controls. Autoradiog-
raphy was used to quantify radioligand binding to VMAT2, VAChT, the dopamine
plasmalemmal transporter (DAT), benzodiazepine (BZ) binding sites, and D2-type dopa-
mine receptors. The activity of choline acetyltransferase (ChAT) was determined as an
additional marker of cholinergic neurons. Autoradiograms were analyzed by video-assisted
densitometry and assessment of atrophy was made from regional structural areas in the
coronal projection. Striatal VMAT2, DAT, and VAChT concentrations were unchanged or
increased, while D2 and BZ binding and ChAT activity were decreased in HD. After atrophy
correction, all striatal binding sites were decreased. However, the decrease in ChAT activity
was 3-fold greater than that of VAChT binding. In addition to degeneration of striatal
projection neurons, there are losses of extrinsic nigrostriatal projections and of striatal
cholinergic interneurons in HD on the basis of vesicular transporter measures. There is also
markedly reduced expression of ChAT by surviving cholinergic striatal interneurons.
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INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant
disorder characterized by slowly progressive motor,
cognitive, and behavioral disturbances (Folstein,
1989). Each individual with an affected parent has a
50% chance of inheriting the HD gene and eventually
manifesting the illness. Macroscopically, there is pro-
gressive brain atrophy with disproportionate striatal
involvement in HD (Vonsattel et al., 1985). Neuro-
chemical studies of the HD striatum suggest that
intrinsic neurons are lost, while the terminals of ex-
trinsic dopaminergic nigrostriatal projections are rela-
tively preserved (McGeer et al., 1973; Perry et al.,
1973; Bird and Iversen, 1974; Spokes, 1980; Ferrante
et al., 1986). This observation led investigators to de-
velopment of excitotoxic models of HD (Portera-Cail-
liau et al., 1995). However, there is conflicting evidence
for the involvement vs. relative sparing of striatal cho-
linergic interneurons (McGeer et al., 1973; Bird and
Iversen, 1974; Kanazawa et al., 1985; Ferrante et al.,
1987a). Enzyme activity of choline acetyltransferase
(ChAT) is markedly reduced in prior studies of HD
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(Spokes, 1980), while histological analyses suggest rel-
ative preservation of the large aspiny striatal neurons
believed to be the cholinergic interneuronal phenotype
(Kanazawa et al., 1985; Ferrante et al., 1987a).
In 1993, the HD Collaborative Research Group
identified the gene and mutation responsible for HD
(Huntington’s Disease Collaborative Research Group,
1993). The HD gene defect is a trinucleotide repeat
(CAG) expansion on chromosome 4p16.3 that encodes a
protein now designated huntingtin. However, contrary
to initial expectations, huntingtin is synthesized
widely throughout the brain and body (Li et al., 1993).
The differential vulnerability of neuronal subpopula-
tions in HD remains to be explained. Neurochemical
markers identifying both preferentially affected and
relatively spared neurons are thus of continued impor-
tance in HD research. Detailed investigations of
marker enzymes and binding sites may lead not only to
improved postmortem understanding of HD neurode-
generation (Bird, 1980; Ferrante et al., 1987a,b), but
may also afford targets for in vivo imaging of HD and
its progression (Holthoff et al., 1993; Turjanski et al.,
1995; Weeks et al., 1996; Bohnen et al., 2000).
In the present study, we examined the relation-
ships of vesicular transporter measures as markers
of the integrity of presynaptic cholinergic synapses
(the vesicular acetylcholine transporter; VAChT) and
dopaminergic synapses (the vesicular monoaminer-
gic transporter type-2; VMAT2) in HD striatum.
These measures are compared to parallel assays of
neurotransmitter receptors and enzymes reported
previously in HD. In addition, we estimated the con-
tribution of striatal atrophy to the measures of stri-
atal marker concentrations, to better reflect the ac-
tual losses of neurons and synapses and to correlate
with expected results of in vivo neurochemical imag-
ing studies in HD.
MATERIALS AND METHODS
Effect of postmortem delay
Possible effects of postmortem delay to tissue pro-
curement and freezing were assessed in experimental
animals under conditions mimicking human postmor-
tem conditions. Adult male Sprague Dawley rats
weighing approximately 200 g were killed by decapita-
tion and the heads maintained at controlled tempera-
ture, mimicking the typical human postmortem cooling
curve as described previously (Whitehouse et al., 1984).
At 0, 4, 8, and 24 h postmortem, groups of brains were
dissected, frozen on dry ice, and covered with frozen
section embedding medium to prevent desiccation.
Brains were then stored in plastic bags at 270°C until
cryostat sectioning. Each brain was sectioned in the
coronal plane using a cryostat microtome at approxi-
mately 220°C. Pairs of adjacent 20 m-thick sections
through the head of the caudate nucleus were thaw-
mounted on poly-L-lysine-subbed microscope slides
and air-dried. Slides were then stored at 270°C until
use in binding assays.
Collection of human brain tissue
All brain tissues used in this study were obtained
from the Michigan Alzheimer’s Disease Research Cen-
ter (MADRC) Brain Bank. Brains were obtained from
four patients (average age, 59 6 10 years) with clini-
cally diagnosed HD. Each HD subject (or their legal
guardian) gave informed consent for brain donation
prior to death. One HD patient (Patient 1, Table I) had
been treated chronically with reserpine until the time
of death (Table I) and was excluded from group assess-
ments of VMAT2 and the dopamine plasmalemmal
transporter (DAT) since prior studies have indicated
significant lasting effects on these measures (Naudon
et al., 1995; Koeppe et al., 1999). Five elderly subjects
(average age, 67 6 15 years) with no neurological or
psychiatric disorders were obtained from The Univer-
sity of Michigan Hospitals autopsy service after in-
formed consent of the next-of-kin and served as con-
trols (Table I).
Brains were removed, hemispheres divided, and
coronal slabs cut from one hemisphere and frozen for
biochemical assays. Slabs were frozen rapidly over liq-
uid nitrogen vapors, sealed in plastic to prevent desic-
cation, and stored at 270°C. The contralateral hemi-
spheres were fixed and processed for routine
neuropathological examination to verify the clinical di-
agnoses. The postmortem delay time was 18 6 6 h for
the controls and 6 6 2 h for the HD patients.
Human tissue preparation for autoradiography
Blocks of brain tissue were identified and dissected
corresponding to the head of the caudate nucleus, pu-
tamen, and nucleus accumbens (at the level of the
decussation of the anterior commissure), the mid-
globus pallidus (including the posterior putamen), the
cerebellar hemispheric cortex, and the superior gyrus
of the frontal cortex. Each tissue block was sectioned
coronally in a cryostat microtome at 220°C. Series of
adjacent 20 m-thick brain sections were thaw-mounted
onto poly-L-lysine-coated microscope slides, dried, and
stored at 270°C until use in autoradiographic assays.
Additional brain sections were collected in the frozen
state and stored in test tubes at 270°C for later enzy-
matic assays.
Autoradiographic ligand binding assays
Slide-mounted brain sections were incubated in
one of a variety of radioligands under conditions that
maximize and define specific binding for each assay
(Table II). After incubation, slides were washed to
remove nonspecific binding and dried. The radiola-
beled sections were then apposed to tritium-sensitive
film (Hyperfilm-3H, Amersham, Arlington Heights,
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IL) in lightproof X-ray cassettes along with tritium-
labeled plastic standards (Pan et al., 1983). After
appropriate exposure times, the films were developed
with Kodak D-19 developer, fixed, and analyzed by
densitometry.
Autoradiograms were analyzed by video-assisted
densitometry (MCID M5 System; Imaging Research,
St. Catherines, Ontario, Canada) using calibrated plas-
tic standards to convert film density to apparent tissue
radioactivity levels as described previously (Pan et al.,
1983).
Regional cross-sectional areas (mm2) were also de-
termined from the digitized images of the basal ganglia
structures for each subject. The nuclear areas were
measured on images generated by the radioligands dis-
playing the best contrast. Structural atrophy was as-
sessed in each HD patient by expressing the individual
brain regional area relative to the mean of the control
group for that region.
Choline acetyltransferase activity
ChAT activity was measured by the formation of
[14C]acetylcholine from [l-14C]acetyl-coenzyme-A and
choline as described previously (Fonnum, 1975). Fro-
zen tissue sections were homogenized in saline and
aliquots assayed for enzyme activity and for protein
concentration by the dye binding method of Smith et al.
(1985) in which bicinchoninic acid is used to stabilize
the reaction product.
Statistical analysis
All data are reported as group mean 6 SD. In addi-
tion to assessments of neurochemical marker activities
and levels per unit tissue, autoradiographic measures
were analyzed after correction for structural atrophy.
To reduce between-subject variability in ChAT enzyme
activity measures, data were additionally evaluated
after within-subject expression relative to the frontal
cortex. In the present data as well as in prior reports













death Grade1 Medications2 Brain regions available
1 F 72 7 10 Infarction of
pons
3 diazepam, 4 mg BID; chlorpromazine,
100 mg TID; reserpine, 0.25 mg QD
FCtx, Caud, APut, PPut,
GP, Cbl
2 M 49 9 11 Pneumonia 4 levodopa/carbidopa, 25/100 mg TID FCtx, Caud, APut, PPut,
GP, Cbl
3 M 56 4 9 Dehydration 3 — FCtx, Caud, APut, PPut,
GP, Cbl
4 F 61 6 10 Septicemia 4 haloperidol, 6 mg QID FCtx, Caud, APut, PPut,
GP, Cbl
Mean 59 6* 10
SD 10 2 1
Control
subjects
1 M 43 9 — Septicemia — — FCtx, Caud, APut, PPut,
GP, Cbl
2 M 67 18 — MI — — FCtx, Caud, APut, PPut,
GP, Cbl
3 M 72 26 — Septicemia — — FCtx, Caud, APut, PPut,
GP, Cbl
4 M 70 16 — Pneumonia — — FCtx, Caud, APut, Cbl
5 F 85 21 — Pneumonia — — FCtx, PPut, GP
Mean 67 18
SD 15 6
*P 5 0.011 vs. control.
APut 5 anterior putamen; Caud 5 caudate nucleus; Cbl 5 cerebellar cortex; FCtx 5 frontal cortex; GP 5 globus pallidus; HD 5 Huntington’s disease; MI 5
myocardial infarction; PMD 5 postmortem delay to tissue freezing; PPut 5 posterior putamen.
1Grading of striatal atrophy in HD proposed by Vonsattel et al. (1985).
2Medications used regularly within 6 months of autopsy with CNS actions. Does not include medications received during resuscitation immediately prior to death.












VAChT [3H]vesamicol (10) 35 MABV (0.2) 60/25 2/1/4 Bianchi et al., 1997
D2 receptor [3H]raclopride (2) 78.4 NMS (10) 60/25 3/5/4 Kohler and Radesater, 1986
BZ receptor [3H]flumazenil (5) 87 clonazepam (5) 30/25 2/5/4 Burdette et al., 1995
VMAT2 [3H]MTBZ (10) 82 TBZ (10) 60/25 2/2/4 Vander Borght et al., 1995b
DAT [3H]WIN 35,428 (3) 84.5 nomifensine (10) 60/4 2/1/4 Canfield et al., 1990
BZ 5 benzodiazepine; D2 receptor 5 type-2 dopamine receptor; DAT 5 dopamine plasmalemmal transporter; MABV 5 methylaminobenzovesamicol; MTBZ 5
methoxytetrabenazine; NMS 5 N-methylspiroperidol; P.I. washing 5 postincubation washing; TBZ 5 tetrabenazine; VAChT 5 vesicular acetylcholine transporter;
VMAT2 5 vesicular monoamine transporter type-2; WIN 35,428 5 2-b-carbomethoxy-3b-(4-fluorophenyl)tropane.
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(Bird and Iversen, 1974; Wong et al., 1982), neocortical
ChAT activity is unaffected in HD. Differences between
groups were assessed with Student’s t-test, employing
a significance threshold of P , 0.05.
RESULTS
Effect of postmortem delay on neurochemical
marker autoradiography
Binding assays for benzodiazepine (BZ) receptors,
DAT, and the vesicular transporters VAChT and
VMAT2 were not significantly affected by postmortem
delays of at least 24 h in the rat brain under conditions
mimicking human postmortem cooling (Fig. 1). Be-
tween 4–24 h of postmortem delay, there were less
than 3% losses of VMAT2, DAT, or VAChT bindings,
while there was a nonsignificant mean loss of 9% of BZ
receptors. Thus, the group differences in postmortem
delay in the human assays are not likely to have con-
tributed spurious findings, nor to have masked signif-
icant neurochemical losses in HD.
Nigrostriatal dopaminergic markers
VMAT2 concentration, as assessed by binding of
[3H]methoxytetrabenazine (MTBZ), was increased sig-
nificantly in the caudate nucleus (71% increase) and in
the anterior (72%) and posterior putamen (25%) in HD
(Fig. 2, Table III). Binding of MTBZ was reduced
throughout the striatum in the subject excluded due to
reserpine exposure (see Table III), attributable to the
irreversible VMAT2 blockade. DAT concentration, as
measured by [3H]WIN 35,428 binding, was increased
by 33% in the caudate, 58% in the anterior putamen,
and by 29% in the posterior putamen. DAT binding
estimates were reduced by over 4 SD in the excluded
HD subject treated with reserpine relative to the re-
maining HD patients. After the introduction of atrophy
correction, both DAT and VMAT2 demonstrated abso-
lute mean striatal losses of 33–56%, achieving statisti-
cal significance for DAT reduction in the posterior pu-
tamen (39% reduction).
Intrinsic striatal markers
Autoradiographic measures of BZ receptor concen-
trations were significantly reduced throughout the HD
striatum by 48–75% (Fig. 2, Table III). The reduction
in posterior putamen was almost twice as great as that
observed in the anterior striatal regions. In the globus
pallidus, BZ receptor concentration was increased over
control by almost 200%. Dopamine D2 receptor concen-
tration was also reduced throughout the striatum,
achieving statistical significance in the anterior (24%
reduction) and posterior putamen (33% reduction). Un-
like the BZ receptors, the reduction of D2 binding was
relatively uniform across the striatal subregions. After
introduction of atrophy correction, both absolute BZ
and D2 receptor numbers were further reduced in all
striatal regions. The increased BZ receptor binding
concentration in the globus pallidus was indicative of
only 33% absolute increase in binding sites after cor-
rection for structural atrophy.
Extrastriatal benzodiazepine receptor binding
Flumazenil (FMZ) binding to BZ receptors in the HD
frontal cortex was normal (Table III). Conversely, bind-
ing in the HD cerebellar cortex was increased signifi-
cantly by 28%.
Presynaptic cholinergic indices
Binding assays of VAChT concentration revealed
nonsignificant increases per unit tissue throughout the
striatum and were normal in the HD frontal cortex and
cerebellum (Fig. 2, Table III). After introduction of
atrophy correction, absolute VAChT binding was re-
duced throughout the striatum, achieving significance
in the anterior (53% reduction) and posterior (33%
reduction) putamen. Measures of ChAT activity per
unit tissue were essentially normal in HD frontal cor-
tex and cerebellum (Table IV), while there were non-
significant trends toward reductions in the caudate
nucleus and putamen. After expression of enzyme ac-
tivity relative to frontal cortex, statistically significant
ChAT reductions were identified in the caudate nu-
cleus (71% reduction) and in the posterior putamen
(81% reduction). The opposing directions of ChAT and
VAChT changes in the HD striatum resulted in a sig-
nificant, nearly 4-fold, reduction in the relative ChAT-
to-VAChT ratio in the caudate nucleus. After expres-
sion relative to the frontal cortex marker activities, the
Fig. 1. Effect of simulated human postmortem delay to brain dis-
section and freezing on autoradiographic binding measures in rat
striatum. Bindings of [3H]MTBZ to VMAT2 sites (F), of [3H]WIN
35,428 to DAT (}), of [3H]vesamicol to VAChT (■), and of [3H]fluma-
zenil to benzodiazepine binding sites (Œ) are depicted at various
postmortem intervals relative to binding in immediately dissected
and frozen tissues. Data represent the mean and SD of five subjects at
each time point. There are no significant changes in the apparent
binding densities of any of the markers studied with postmortem
delays up to 24 h.
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ChAT-to-VAChT ratios were found significantly re-
duced in the caudate nucleus (80% reduction) and in
the posterior putamen (83% reduction).
DISCUSSION
Selectivity of neuronal degeneration in HD
Our results confirm marked losses of intrinsic stria-
tal synaptic markers in HD including BZ (Walker et al.,
1984; Kanazawa et al., 1985; Whitehouse et al., 1985;
Ellison et al., 1987; Reynolds et al., 1990) and dopa-
mine D2 (Whitehouse et al., 1985; Brandt et al., 1990;
Richfield et al., 1991; Ichise et al., 1993; Weeks et al.,
1996) receptors. Contrary to initial reports, however,
we find evidence that degeneration is not confined to
the striatal projection neurons alone and does not af-
fect all striatal neurons equally. We find evidence for
losses in nigrostriatal projection terminals, as reflected
in reduced absolute numbers of VMAT2 binding sites.
In addition, we have novel evidence for dissociation of
the two presynaptic cholinergic neurochemical mark-
ers, ChAT and VAChT, reconciling discrepant prior
data (Kish et al., 1990; Ruberg et al., 1990; Murman et
al., 1994) on cholinergic interneurons in HD. Together,
these results confirm that there are selective effects on
GABAergic striatal projection neurons in HD, but that
the pathology is only relatively, rather than absolutely,
selective.
Original neurochemical analyses of HD striatum re-
vealed normal or elevated levels of dopamine and re-
lated synthetic enzymes, suggesting preservation of
the nigrostriatal projection (Bernheimer et al., 1973;
McGeer and McGeer, 1976; Spokes, 1980; Albin et al.,
1990). Experimental animal models of HD employing
glutamatergic excitotoxins reveal similar preservation
or elevation of nigrostriatal markers per unit tissue of
lesioned striatum (Gehlert and Schoepp, 1992). Other
studies, however, have suggested that substantia nigra
pars compacta neurons are lost in HD (Oyanagi et al.,
1989; Gibb, 1991). Some investigators have also re-
ported losses of dopamine and of its metabolite ho-
movanillic acid (Kish et al., 1987). In the present stud-
ies, we have confirmed prior observations that striatal
presynaptic dopaminergic markers are increased per
unit tissue in HD. Before atrophy correction, the bind-
ing site concentrations of DAT and of VMAT2 in the
putamen were significantly increased. However, after
atrophy correction the absolute numbers of these
markers were decreased throughout the striatum,
achieving statistical significance in the posterior puta-
men for VMAT2 reduction. While interpretation of re-
Fig. 2. Vesicular neurotransmitter transporter autoradiography.
Representative autoradiograms of striatal nuclei from HD are de-
picted in the top row (A–C) and comparison normal samples are in the
bottom row (D–F). In each image pair, the leftmost section includes
the caudate nucleus and anterior putamen and the rightmost section
includes the posterior putamen and globus pallidus. VMAT2 (A,D),
VAChT (B,E), and benzodiazepine binding site (C,F) concentrations
are displayed in pseudocolor according to the scale at the bottom right
(red 5 highest binding; violet 5 lowest binding). Note increased
concentrations of VMAT2 and VAChT and marked atrophy in caudate
and putamen. After adjustment for atrophy, both vesicular transport-
ers are reduced in HD relative to control (see text, Table III). Benzo-
diazepine binding is reduced in striatum and increased in globus
pallidus.
TRANSPORTERS IN HD 333
duced DAT binding includes either a reduced density of
dopaminergic nerve terminals or reduced DAT expres-
sion per terminal, prior work in experimental animals
indicates that the latter is not likely for VMAT2
(Vander Borght et al., 1995a). Our findings of reduced
VMAT2 in the striatum therefore strongly favor losses
of nigrostriatal terminals in HD. In vivo DAT imaging
is in agreement with our atrophy-corrected projections,
indicating a 50% loss of binding in HD striatum (Gino-
vart et al., 1997). Recent in vivo studies with the
VMAT2 ligand [11C]dihydrotetrabenazine also indicate
loss of dopamine terminals, particularly in the poste-
rior putamen (Bohnen et al., 2000).
Histological studies indicate relative preservation of
large aspiny interneurons in HD striatum that are
associated with the cholinergic phenotype in normal
subjects (Lange et al., 1976; Parent et al., 1984; Ka-
nazawa et al., 1985; Ferrante et al., 1987a). However,
neurochemical assays reveal significant reductions of
the marker enzyme ChAT, suggesting degeneration of
the striatal cholinergic neurons (Bird and Iversen,
1974; McGeer and McGeer, 1976; Spokes, 1980; Ka-
nazawa et al., 1985; Hirsch et al., 1989).
Our present measurements of cholinergic markers
confirm the findings of the prior ChAT activity studies
and, importantly, provide explanation for the apparent
discrepancy between enzymology and histopathology of
the striatal cholinergic interneurons. Our measures of
VAChT binding indicate that there is a significant dis-
sociation of vesicle transporter levels from ChAT activ-
ity. We observed a 3–4-fold difference in the relative
measures of striatal ChAT and VAChT in HD relative
TABLE III. Striatal synaptic markers before and after correction for atrophy
Neurochemical
marker Group











Control (n 5 4) 40 6 4 59 6 9 72 6 8 5 6 1 8 6 2 8 6 12
VAChT HD (n 5 4) 55 6 12 69 6 24 105 6 34 14 6 4* 6 6 2 7 6 1
HD corrected1 (n 5 4) 19 6 14 28 6 9** 48 6 7** 7 6 3 — —
Control (n 5 4) 64 6 4 77 6 10 62 6 13 31 6 3 130 6 5 267 6 322
BZ receptor HD (n 5 4) 33 6 20* 40 6 6** 16 6 5** 93 6 31 166 6 22* 292 6 10
HD corrected1 (n 5 4) 12 6 9** 19 6 11** 8 6 2** 45 6 22 — —
Control (n 5 4) 13 6 1 13 6 1 15 6 3 3 6 2 — —
D2 receptor HD (n 5 4) 10 6 3 10 6 1* 10 6 3* 3 6 1 — —
HD corrected1 (n 5 4) 4 6 2** 5 6 3** 5 6 2** 1 6 1 — —
Control (n 5 4) 109 6 25 109 6 14 155 6 21 9 6 1 — —
VMAT2 HD3 (n 5 3) 186 6 65 187 6 35* 193 6 81 18 6 6 — —
HD corrected1 (n 5 3) 58 6 37 70 6 31 94 6 11** 9 6 4 — —
Control (n 5 4) 45 6 12 43 6 11 49 6 5 3 6 1 — —
DAT HD4 (n 5 3) 60 6 8 68 6 6* 63 6 15 5 6 2 — —
HD corrected1 (n 5 3) 20 6 13 27 6 16 33 6 14 3 6 1 — —
*P , 0.05 vs. control.
**P , 0.01 vs. control.
BZ 5 benzodiazepine; D2 receptor 5 type-2 dopamine receptor; DAT 5 dopamine plasmalemmal transporter; HD 5 Huntington’s disease; VAChT 5 vesicular
acetylcholine transporter; VMAT2 5 vesicular monoamine transporter type-2.
1Atrophy assessment revealed significant (P , 0.02 or lower) area losses of 66 6 15% in the caudate nucleus, of 54 6 23% in the anterior putamen, of 45 6 14%
in the posterior putamen and of 55 6 9% in the globus pallidus of HD relative to controls.
2N 5 5 subjects studied in this region.
3Values obtained in the excluded HD subject receiving reserpine treatment (Subject #1, Table I): caudate-130; anterior putamen-168; posterior putamen-185; globus
pallidus-19.
4Values obtained in the excluded HD subject receiving reserpine treatment (Subject #1, Table I): caudate-20; anterior putamen-23; posterior putamen-24; globus
pallidus-5.










ChAT Control (n 5 4) 75 6 25 109 6 69 104 6 56 4 6 3 4 6 11
HD (n 5 4) 31 6 40 54 6 89 33 6 57 3 6 5 4 6 2
VAChT Control (n 5 4) 40 6 4 59 6 9 72 6 8 8 6 2 8 6 11
HD (n 5 4) 55 6 12 69 6 24 105 6 34 6 6 2 7 6 1
ChAT/VAChT Control (n 5 4) 1.9 6 0.5 1.8 6 1.0 1.4 6 0.7 0.5 6 0.2 0.5 6 0.11
HD (n 5 4) 0.5 6 0.6* 0.9 6 1.6 0.4 6 0.8 0.4 6 0.6 0.5 6 0.3
Relative to frontal cortex
ChAT Control (n 5 4) 21 6 5 30 6 16 27 6 12 1 6 1
HD (n 5 4) 6 6 5** 9 6 12 5 6 8* 1 6 1
VAChT Control (n 5 4) 4.7 6 0.8 6.9 6 1.3 9.1 6 2.5 1.0 6 0.3
HD (n 5 4) 7.7 6 2.3 9.5 6 3.8 15.1 6 7.2 0.8 6 0.2
ChAT/VAChT Control (n 5 4) 4.4 6 0.5 4.3 6 1.8 2.9 6 0.7 1.0 6 0.3
HD (n 5 4) 0.9 6 0.7** 1.2 6 1.7 0.5 6 0.8** 0.7 6 0.5
*P , 0.05 vs. control.
**P , 0.01 vs. control.
ChAT 5 choline acetyltransferase enzyme activity (nmol/h/mg protein); HD 5 Huntington’s disease; VAChT 5 vesicular acetylcholine transporter radioligand
binding (dpm/mg protein).
1N 5 5 subjects studied in this region.
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to control striatum, suggesting decreased enzyme ac-
tivity in neurons that continue to express vesicular
transporters for acetylcholine. Studies from our labo-
ratory on VAChT radioligand binding indicate that it is
specific for cholinergic presynaptic terminals and that
the expressed level of VAChT binding is not regulated
during chronic cholinesterase inhibition or muscarinic
cholinergic receptor blockade (Bianchi et al., 1997).
Thus, the present findings suggest relative preserva-
tion of cholinergic interneurons in HD striatum, in
keeping with histological observations, but with dimin-
ished ChAT activity. However, our data further indi-
cate that there are losses of cholinergic interneurons in
HD. After introduction of atrophy correction, the rela-
tively increased striatal concentration of VAChT bind-
ing per unit tissue corresponds to a reduction by at
least 50% in total striatal VAChT binding. Thus, our
data confirm the relative structural sparing of cholin-
ergic interneurons in HD, but indicate that actual
losses are comparable to those in extrinsic nigrostriatal
projections, as discussed previously.
Postmortem delay
There is a significant difference of postmortem dura-
tion between the HD and comparison groups in our
study. This difference would be expected to bias in
favor of smaller distinctions between the groups if the
predominant effect of postmortem delay is proteolysis
and loss of tissue integrity. We directly assessed the
possible effect of postmortem delay on the measured
binding assays in an experimental animal model. We
found no significant alterations of BZ receptor antago-
nist binding and no significant alterations in bindings
of ligands to the DAT or to the vesicular transporters
VMAT2 and VAChT. We therefore interpret the results
of the human postmortem tissue assays as representa-
tive of disease- and treatment-related changes, rather
than of postmortem effect.
Striatal atrophy adjustment
We introduced adjustments of our binding measures
for the effects of atrophy in the basal ganglia nuclei as
assessed autoradiographically. It is important to note
that these corrections are at best approximate, since
they reflect only changes in cross-sectional area in the
coronal plane. In order to more accurately adjust for
atrophy, regular sampling throughout the rostro-cau-
dal extent of each nucleus would be necessary. How-
ever, this sampling frequency is beyond the scope of our
present experiments. The estimates of atrophy made in
two dimensions in our present calculations are very
likely to underestimate its actual impact. If, for exam-
ple, atrophy were equivalent in the rostro-caudal di-
mension to that in the coronal sections, actual striatal
volume reductions would be approximately 15%
greater (assuming 30% radial shrinkage and spherical
geometry of the measured nuclei). Despite likely un-
dercorrection for tissue atrophy, our results demon-
strate significant losses of all neuronal markers in HD
striatum, including projection neurons, cholinergic in-
terneurons, and nigrostriatal terminals.
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